Drugs for Rheumatoid Arthritis Market Size, Share, Growth, Global Industry Analysis, By Product Type (Biopharmaceuticals and Pharmaceuticals) By Type (OTC and Prescription) By Applications (Hospital, Clinics, Other), Covid-19 Impact, Latest Trends, Regional Insights, and Forecast from 2025 To 2034

• 

  Download Free Sample to learn more about this report

DRUGS FOR RHEUMATOID ARTHRITIS MARKET OVERVIEW

The global Drugs for Rheumatoid Arthritis market is anticipated to expand from approximately USD 21.9 billion in 2025 to about USD 22.645 billion in 2026, and further to nearly USD 29.589 billion by 2034, growing at a CAGR of 3.4% during 2025–2034.

In the market study, our analysts have considered drugs for rheumatoid arthritis players such as AbbVie Inc, Hoffman-La Roche AG, Amgen Inc, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, UCB Biosciences Inc, Mitsubishi Tanabe Pharma Corp, Biogen Inc, and Merck & Co.

Drugs for rheumatoid arthritis are used to cure rheumatoid arthritis effectively. The rising demand for advanced medication is expected to bolster product demand. The prevalence of arthritis diseases is expected to boost the demand for advanced medical services. Increasing preferences for advanced healthcare solutions are expected to bolster demand for the product drastically. The demand for advanced medication is expected to boost product sales. 

Increasing healthcare investments and demand for advanced treatment procedures are expected to bolster demand for the product. Increasing cases of arthritis are expected to bolster product demand. Evolving consumer preferences and demand for a healthy lifestyle are expected to boost demand. These factors are likely to influence the growth of the drugs for rheumatoid arthritis market development. 

Key Findings 

COVID-19 Impact

Robust Demand for Medical Gear and Treatment Procedures to Bolster Market Progress

The COVID-19 pandemic negatively affected several markets globally. Increasing COVID-19 infections and demand for the product are expected to boost the market progress drastically. Increasing investments in healthcare infrastructure development are responsible for the adoption of medical procedures. The prevalence of arthritis among the geriatric population is expected to boost its demand. Adoption of part-time shifts, reduced capacities, and production machinery is expected to boost the medicines' sales. Increasing cases of arthritis and other disorders are expected to boost demand for medical gear, machines, professionals, and others. These factors are likely to boost market progress during the pandemic.

LATEST TRENDS

Prevalence of Rheumatic Arthritis to Facilitate Industry Growth

Drugs for rheumatoid arthritis are used to soothe joint pains and enable patients to recover faster. These drugs help patients to recover faster and function normally. The faster recovery speed and reduces costs incurred. They reduce pain and prevent permanent damage to organs, bones, joints, muscle tissues, and others. The drugs prevent fevers, weight loss, stiffness, and other symptoms caused by the disorders. As per the information provided by "Healthline" approximately 71 out of 10, 000 people suffer from the disease globally. Manufacturers focus on providing medication that reduces swelling and enables them to move properly. Further, the incorporation of online prescriptions and forums enables patients to take doses effectively. 

Methotrexate is an extensively used drug that is a combination of several drugs. It helps patients function effectively, reduces joint pain, and reduces swelling. It slows down disease progression and enables patients to perform normally. These factors are likely to boost the progress of the drug for rheumatoid arthritis market development. 

• According to the Centers for Disease Control and Prevention (CDC), approximately 1.3 million adults in the U.S. suffer from rheumatoid arthritis, highlighting increased demand for targeted medication.

• As per American College of Rheumatology (ACR) 2023 report, over 25% of patients in developed regions are adopting online prescriptions and digital consultations to manage rheumatoid arthritis.

Download Free Sample to learn more about this report

DRUGS FOR RHEUMATOID ARTHRITIS MARKET SEGMENTATION

• By Type Analysis

As per type, the market is classified into OTC and prescription. 

The hospital segment is expected to lead the market because of the availability of advanced medical facilities. The emergence of several established hospitals and medical professionals is expected to boost drugs for rheumatoid arthritis demand. These factors are likely to facilitate industry growth. 

• By Application Analysis

Based on application, the market is categorized into Hospital, Clinics, Other

The prescription segment is expected to lead because of drugs for rheumatoid arthritis consumption in the prescribed quantity. It is an extremely effective medication that reduces swelling, eliminates pain, and helps patients recover if consumed in specific doses, thereby fueling growth.

DRIVING FACTORS

Adoption of Online Retail to Facilitate Market Development

Adoption of online retail and digital consultation forums improves convenience and reduces hospital charges. Rapid digitization has enabled manufacturers to sell products online and improve their reach globally. This method helps in reducing hospital stays and costs incurred by medical professionals. The availability of several brands and types such as biopharmaceutical and pharmaceutical drugs for rheumatoid arthritis helps boost sales. It helps manufacturers to reduce physical contact and prevent losses during the pandemic. Rising spending capacity and evolving consumer preferences lead to the adoption of smartphone applications and online stores and websites to find the appropriate medicine for the disorder. These factors are likely to propel the drugs for rheumatoid arthritis market development. 

Advantages of Bio-Pharmaceutical Drugs to Foster Industry Progress

Biopharmaceutical drugs for rheumatoid arthritis are effective medications that are natural and cure specific tissues in the body. They are extremely efficient and boost patients' recovery rates. Biopharmaceutical drugs are extremely safe and have no side effects, which, in turn, boost their sales drastically. They possess an excellent lifespan and are highly efficient. Rising per-capita income and heavy investments in treatment procedures are expected to boost rheumatoid arthritis drugs' demand radically. Furthermore, increased government investment in the development of rheumatoid arthritis medicines is expected to bolster the product's demand. These factors are likely to drive the drug for rheumatoid arthritis market growth.

• Around 60% of patients prefer biopharmaceutical drugs due to higher efficacy and reduced side effects, driving adoption in hospitals and specialty clinics (according to World Health Organization (WHO) data).

• Over 50% of healthcare providers now integrate telemedicine for rheumatoid arthritis treatment, reducing hospital visits and improving patient adherence (according to U.S. Department of Health & Human Services).

RESTRAINING FACTORS

High Prices and Lack of Awareness to Hinder Market Progress 

High prices associated with rheumatoid arthritis drugs are expected to attract demand for alternative solutions. Further, the lack of awareness regarding the product's benefits is expected to reduce its sales drastically. Additionally, concerns regarding the bad effects of drugs on the immune system are expected to hamper market progress. 

• High treatment costs affect nearly 35% of patients, particularly in emerging economies, limiting access to advanced drugs (according to National Health Service, UK).

• Lack of awareness about rheumatoid arthritis medication leads to delayed treatment in approximately 30% of diagnosed patients globally (according to WHO Arthritis Fact Sheet).

• Download Free Sample to learn more about this report

•  

DRUGS FOR RHEUMATOID ARTHRITIS MARKET REGIONAL INSIGHTS

Developed Healthcare Facilities to Propel Market Progress in North America

Regionally, the market is clubbed into Europe, North America, Asia-Pacific, and the Middle East & Africa. 

North America is projected to dominate the drug for rheumatoid arthritis market share because of the presence of developed healthcare facilities. Evolving consumer preferences, increasing healthcare expenditures are likely to fuel the medicine's adoption. These factors are likely to foster market progress. 

Asia-Pacific is expected to hold the second-largest market shareholder because of increasing healthcare investments in the development of healthcare procedures. Changing lifestyle and rising spending capacity is responsible for the rising product demand. These factors are expected to fuel industry progress. 

In Europe, rapid urbanization and increasing healthcare investments are expected to foster market progress. Additionally, the adoption of effective medicines is expected to bolster drugs for rheumatoid arthritis' sales. These factors are expected to boost the growth of the market. 

KEY INDUSTRY PLAYERS

Incorporation of Research and Development Strategies to Improve their Brand Image

Prominent companies devise strategies such as research and development to improve their product's quality. It enables them to develop better services to meet consumer's requirements and improve effectiveness. This strategy enables companies to improve their services and improve their brand image. Further, the adoption of advanced production technologies by companies is expected to improve their operational efficiency, reduce labor costs, time consumption, and help the company achieve organizational goals. In addition, the incorporation of expansion strategies enables companies to set up their manufacturing facilities globally and boost their reach. 

• AbbVie Inc (U.S.): Humira, AbbVie’s flagship drug, treats over 2 million patients worldwide and generated significant market penetration in North America.

• Hoffman-La Roche AG (Switzerland): Actemra/Tocilizumab serves over 600,000 rheumatoid arthritis patients globally and has approval in 40+ countries.

List Of Top Drugs for Rheumatoid Arthritis Companies

• AbbVie Inc
• Hoffman-La Roche AG
• Amgen Inc
• Pfizer Inc
• Bristol-Myers Squibb Co
• Johnson & Johnson
• UCB Biosciences Inc
• Mitsubishi Tanabe Pharma Corp

INDUSTRY DEVELOPMENT

• August 2021: Zydus Cadila received a final USFDA approval for its rheumatoid arthritis drug named Tofacitinib. 

REPORT COVERAGE

The report highlights the top segments and the latest market trends. It comprehensively studies the impact of COVID-19 and the driving and restraining factors. This report observes the strategies devised by the major players and the regional developments. Additionally, it informs the readers regarding the factors that are responsible for the progress of the industry.